Balz, Kathrin
Kaushik, Abhinav
Cemic, Franz
Sampath, Vanitha
Heger, Vanessa
Renz, Harald
Nadeau, Kari
Skevaki, Chrysanthi
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft
Deutsches Zentrum für Lungenforschung
Stiftung für Pathobiochemie und Molekulare Diagnostik
Philipps-Universität Marburg
Article History
Received: 6 March 2023
Accepted: 23 August 2023
First Online: 8 September 2023
Competing interests
: For CS: Consultancy and research funding, Hycor Biomedical, Bencard Allergie and Thermo Fisher Scientific; Research Funding, Mead Johnson Nutrition (MJN). For KC: Dr. Nadeau reports grants from National Institute of Allergy and Infectious Diseases (NIAID), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Environmental Health Sciences (NIEHS), and Food Allergy Research & Education (FARE); stock options from IgGenix, Seed Health, ClostraBio, and ImmuneID; is Director of the World Allergy Organization Center of Excellence for Stanford, Advisor at Cour Pharma, Consultant for Excellergy, Red tree ventures, Eli Lilly, and Phylaxis, Co-founder of Before Brands, Alladapt, Latitude, and IgGenix; and National Scientific Committee member at Immune Tolerance Network (ITN), and National Institutes of Health (NIH) clinical research centers, outside the submitted work; patents include, “Mixed allergen composition and methods for using the same,” “Granulocyte-based methods for detecting and monitoring immune system disorders,” and “Methods and Assays for Detecting and Quantifying Pure Subpopulations of White Blood Cells in Immune System Disorders.”